S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases

InVivo Therapeutics Stock Price, News & Analysis (NASDAQ:NVIV)

$0.73
+0.07 (+10.61%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.67
$0.74
50-Day Range
$0.60
$1.19
52-Week Range
$0.60
$2.80
Volume
27,449 shs
Average Volume
48,279 shs
Market Capitalization
$2.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NVIV stock logo

About InVivo Therapeutics Stock (NASDAQ:NVIV)

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

NVIV Stock Price History

NVIV Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
InVivo Therapeutics Holdings Corp NVIV
Why InVivo Therapeutics Shares Are Plunging Today
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Why Is InVivo Therapeutics (NVIV) Stock Down 34% Today?
InVivo Therapeutics Holdings Corp. (NVIV)
See More Headlines
Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/14/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVIV
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Net Income
$-10,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.87 per share

Miscellaneous

Free Float
3,085,000
Market Cap
$2.27 million
Optionable
Not Optionable
Beta
0.86
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Richard M. Toselli (Age 65)
    President, CEO, Chief Medical Officer & Director
    Comp: $825.2k
  • Mr. Richard C. Christopher (Age 53)
    CFO & Treasurer
    Comp: $537.82k
  • Ms. Heather M. Hamel J.D. (Age 33)
    Chief Legal Officer & General Counsel
    Comp: $446.96k
  • Dr. Robert S. Langer Jr. (Age 74)
    Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Joseph Philip Vacanti M.D. (Age 74)
    Co-Founder














NVIV Stock Analysis - Frequently Asked Questions

How have NVIV shares performed in 2023?

InVivo Therapeutics' stock was trading at $2.35 at the beginning of the year. Since then, NVIV shares have decreased by 68.9% and is now trading at $0.73.
View the best growth stocks for 2023 here
.

Are investors shorting InVivo Therapeutics?

InVivo Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,000 shares, a drop of 88.2% from the October 31st total of 8,500 shares. Based on an average trading volume of 12,800 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company's stock are sold short.
View InVivo Therapeutics' Short Interest
.

When is InVivo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024.
View our NVIV earnings forecast
.

How were InVivo Therapeutics' earnings last quarter?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) released its earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.87) earnings per share for the quarter.

When did InVivo Therapeutics' stock split?

InVivo Therapeutics shares reverse split before market open on Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of InVivo Therapeutics own?
How do I buy shares of InVivo Therapeutics?

Shares of NVIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NVIV) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -